{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:50Z","timestamp":1790085710935,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03299-6","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:16:59Z","timestamp":1790083019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early clinical experience with IPX203 in Parkinson\u2019s disease with motor fluctuations"],"prefix":"10.1007","author":[{"given":"S.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"3299_CR1","unstructured":"ADIP Study (2026) EU Clinical Trials Register Identifier: EU CT 2025-521772-57-00"},{"key":"3299_CR2","volume-title":"and levodopa) extended-release capsules [package insert]","author":"CREXONT\u00ae (carbidopa","year":"2024","unstructured":"CREXONT\u00ae (carbidopa (2024) and levodopa) extended-release capsules [package insert]. Amneal Pharmaceuticals LLC, Bridgewater, NJ"},{"key":"3299_CR3","unstructured":"ELEVATE-PD (2026) ClinicalTrials.gov Identifier: NCT06765668"},{"issue":"2","key":"3299_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mds.29685","volume":"39","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Hauser RA, Dhall R et al (2024) Safety and Efficacy of IPX203 in Parkinson\u2019s Disease: The RISE-PD Open-Label Extension Study. Mov Disord 39(2):428\u2013432 PMID: 38111267","journal-title":"Mov Disord"},{"issue":"10","key":"3299_CR5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL et al (2023) IPX203 versus immediate-release carbidopa-levodopa in Parkinson\u2019s disease: the RISE-PD randomized trial. JAMA Neurol 80(10):1062\u20131069","journal-title":"JAMA Neurol"},{"key":"3299_CR6","doi-asserted-by":"publisher","first-page":"107239","DOI":"10.1016\/j.parkreldis.2024.107239","volume":"131","author":"RA Hauser","year":"2025","unstructured":"Hauser RA, Fernandez HH, Jimenez-Shahed J et al (2025) Duration of Good On time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT\u00ae). Parkinsonism Relat Disord 131:107239 PMID: 39733558","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"3299_CR7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.addr.2007.06.016","volume":"59","author":"H Lennern\u00e4s","year":"2007","unstructured":"Lennern\u00e4s H (2007) Human intestinal permeability and transport of amino acids and amino acid analogues including levodopa via the large neutral amino acid transporter. Adv Drug Deliv Rev 59(11):1103\u20131120","journal-title":"Adv Drug Deliv Rev"},{"key":"3299_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2023.100197","volume":"8","author":"P LeWitt","year":"2023","unstructured":"LeWitt P, Ellenbogen A, Burdick D et al (2023) Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clin Parkinsonism Relat Disord 8:100197","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"1","key":"3299_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WNF.0000000000000314","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Rubens R, Khanna S, Gupta S (2019) Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. Clin Neuropharmacol 42(1):4\u20138","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"3299_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/WNF.0000000000000354","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Dinh P, Rubens R, Gupta S (2019) Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. Clin Neuropharmacol 42(5):149\u2013156","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"3299_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5(8):677\u2013687","journal-title":"Lancet Neurol"},{"key":"3299_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"3299_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T et al (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm 132:743\u2013779. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03299-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03299-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03299-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:17:02Z","timestamp":1790083022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03299-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":13,"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03299-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"9 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}